



February 18, 2015

Company Name	3 - D Matrix, Ltd.
Address	3-2-4, Kojimachi, Chiyoda, Tokyo
President	Kentaro Takamura
Code Number	7777
Contact	Director Tomoyuki Arai
T E L	+81 3 (3511)3440

**[Delayed] Suspension of Patient Enrolment in the Clinical Trial of “Mucous Membrane Protuberance Material (TDM-641)”**

(This original disclosure in Japanese was released on February 16, 2014 at 20:30 (GMT+9))

We hereby announce that we have decided to suspend the enrolment of new patients in the on-going clinical trial of the endoscopic mucosal resection aid "Mucous Membrane Protuberance Material (development code: TDM-641)" which has been announced to start in Japan as of December 11, 2014 and that we will notify Pharmaceuticals and Medical Devices Agency, Japan as of February 17, 2015.

This clinical trial began in December 2014 to evaluate and validate the safety and efficacy of TDM-641 as endoscopic mucosal resection aid used in endoscopic treatment (Endoscopic Mucosal Resection; EMR and Endoscopic Submucosal Dissection; ESD).

Since adequate results for the efficacy, as expected from the preclinical data, have not been provided, we have decided to suspend the trial voluntarily in order to review and adjust the product specification.

From now on, we will reconsider the development course in accordance with the results from the review to ensure the advantage for the commercialization of the product, and continue to make the development to enable the trial to be conducted on a continuing basis, in collaboration with the investigators.

This announcement does not influence the earning forecast of the company. However, the group will make necessary announcements when it is deemed that there will be influence on the earning forecast of the company.